adriamycinol has been researched along with epalrestat in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Challa, VS; Gangasani, JK; Jain, S; Kundu, GC; Naidu, VGM; Panda, SR; Rajdev, B; Syamprasad, NP; Vaidya, JR | 1 |
1 other study(ies) available for adriamycinol and epalrestat
| Article | Year |
|---|---|
AKR1B1 inhibition using NARI-29-an Epalrestat analogue-alleviates Doxorubicin-induced cardiotoxicity via modulating Calcium/CaMKII/MuRF-1 axis.
Topics: Aldehyde Reductase; Animals; Apoptosis; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiotoxicity; Doxorubicin; Mice; Myocytes, Cardiac; Oxidative Stress; Rhodanine | 2023 |